2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5979 G-CSF-primed peripheral blood stem cells alone without bone marrow supplementation could achieve satisfactory outcomes in elderly patients with severe aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation: A retrospective registry-based study from Chinese blood and marrow transplantation registry group

Xin Zhao, Lanping Xu, MD2, Shun-Qing Wang3, Xiaojun Huang, MD,PhD4
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
3 Guangzhou First People’s Hospital, Guangzhou, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone in the treatment of aplastic anemia (AA). Bone marrow (BM) transplantation achieves superior survival and a lower incidence of graft-versus-host disease (GvHD) compared to peripheral blood stem cells transplantation (PBSCT) in SAA patients. While the use of peripheral blood stem cells (PBSCs) could facilitate engraftment and avoid donor overexploitation, the increased T-cell content of this graft source may result an increased risk of GvHD. Therefore, international guidelines recommend BM over PB grafts in SAA. In China, the Beijing protocol utilizes granulocyte colony-stimulating factor (G-CSF)-primed bone marrow combined with G-CSF-primed peripheral blood stem cells (G-BM/G-PB mixture) as the standard graft source. The combination of BM and PB successfully exploit the immunological properties of both elements, thereby promoting engraftment while minimizing GVHD. The use of G-CSF-primed stem cells, as the characteristic of this protocol, enriches multipotent hematopoietic progenitor cells and exerts critical immunomodulatory effects.

However, this paradigm changed during the SARS-CoV-2 pandemic due to the logistical unavailability of BM. To meet this challenge, G-PB has been increasingly utilized. By 2024, data from the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) indicate that G-PB has become the predominant source of stem cells, accounting for 57.01% of haploidentical donor (HID) transplants and 71.54% of matched sibling donor (MSD) transplant.

For patients with SAA over 40 years, the standard treatment strategy according to US and European guidelines is immunosuppressive therapy (IST) over HSCT owing to increased risks of graft failure (GF), treatment-related morbidity, and GvHD associated with patient age. With the improvements in supportive care and transplant protocols, favorable survival outcomes with HSCT have been observed in recent years. In previous studies, we reported the outcomes of SAA patients over 40 years of age who underwent HID-HSCT and obtained encouraging results. Despite this, whether removing BM from grafts compromise survival outcomes in elderly patients with SAA remains unclear. Previous observations on graft source selection were primarily based on younger populations, and data specifically assessing the effect of grafts in elderly SAA patients remain scarce.

 

In this retrospective study, we evaluate survival differences in 220 SAA patients aged 40-60 years who received haploidentical-donor (HID) allo-HSCT using either G-CSF-primed PB (G-PB) or G-BM/G-PB mixture. Patients were 40 to 60 years old with an established diagnosis of SAA and received G-BM/G-PB mixture (n = 167) or G-PB (n = 53) from HIDs (n = 220). The distribution of variables, including previous IST with ATG treatment (P = 0.002), Eastern Cooperative Oncology Group (ECOG) score category (P = 0.049), and transplant era separated by 2019 (P = 0.029) were significantly different between two groups. We included them, along with recipient sex, recipient age and donor age in the calculation of the propensity score to adjust for pre-transplant differences. A total of 45 in the PB group and 106 in the G-BM/G-PB mixed group were yielded following 1:3 propensity score matching. We observed similar rates of neutrophil engraftment (93.4% vs. 93.3%, P = 0.700) and platelet recovery (77.8% vs. 78.5%, P = 0.856) after transplantation of G-PB or G-BM/G-PB mixed grafts. There were no significant differences in the cumulative incidences of grades II-IV (13.5% vs. 16.1%, P = 0.643) or grades III-IV acute graft-versus-host disease (acute GVHD; 4.6% vs. 5.7%, P = 0.754) between G-PB and G-BM/G-PB mixed group. The G-BM/G-PB mixed group (6.1%) exhibited similar incidence of moderate to severe chronic GvHD compared to the G-PB group (7.6%) (P = 0.904). The 1-year overall survival of G-PB group and G-BM/G-PB mixed group were 67.2 % vs. 77.5 % (P = 0.129), failure-free survival was 67.2 % vs. 76.6 % (P = 0.178), and GvHD-free/relapse-free survival was 62.9 % vs. 74.7 % (P = 0.106), respectively. In conclusion, our study supports the safety and efficacy of using G-PB as the graft source in HID transplantation for elderly patients with SAA. Prospective trials are required to confirm our findings.

 

 

Xin Zhao: No relevant conflicts of interest to declare.